Value-engineered translation for regenerative medicine: Meeting the needs of health systems

Tania Bubela, Christopher McCabe

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

Despite high expectations of economic returns, large investments in regenerative medicine technology have yet to materialize, partly due to a lack of proven business and investment models, regulatory hurdles, and a greater focus on cost-effectiveness for reimbursement decisions by payors. Adoption of new economic modeling methods will better link investment decisions to value-based criteria of health systems.

Original languageEnglish
Pages (from-to)89-93
Number of pages5
JournalStem Cells and Development
Volume22
Issue numberSUPPL.1
DOIs
Publication statusPublished - 1 Dec 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'Value-engineered translation for regenerative medicine: Meeting the needs of health systems'. Together they form a unique fingerprint.

Cite this